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Abstract
Background/Aims: Combination therapy with interferon-
· (IFN-·) plus ribavirin is more efficacious than IFN-·
monotherapy in previously untreated patients with
chronic hepatitis C and patients with IFN-· relapse. Only
limited data are available in IFN-· non-responders. In a
multicenter trial we therefore evaluated the efficacy of
combination therapy in IFN-·-resistant chronic hepatitis
C. Methods: Eighty-two patients (mean age 46.8 years,
54 males, 28 females) with chronic hepatitis C were
treated with IFN-·-2a (3 ! 6 MIU/week) and ribavirin
(14 mg/kg daily) for 12 weeks. Thereafter, treatment was
continued only in virological responders (undetectable
serum HCV RNA at week 12) with an IFN-· dose of 3 !
3 MIU/week and without ribavirin for a further 9 months.
The primary study endpoint was an undetectable HCV
RNA by RT-PCR at the end of the 24-week follow-up peri-
od. Results: After 12 weeks of combination therapy, an
initial virological response was observed in 29 of 82
(35.4%) patients. Due to a high breakthrough rate after
IFN-· dose reduction and ribavirin discontinuation, an
end-of-treatment response was only achieved in 12 of 82
(14.6%) patients. After the follow-up period, a sustained
virological response was observed in 8 of 82 (9.8%)
patients. Infection with HCV genotype 3 was the only pre-
treatment parameter, which could predict a sustained
response (HCV-1, 5%; HCV-3, 57.1%; p ! 0.001). Conclu-
sions: Despite a high initial response rate of 35.4%, sus-
tained viral clearance was achieved only in 9.8% of the
retreated primary IFN-· non-responders. Higher IFN-·
induction and maintenance dose, as well as prolonged
ribavirin treatment may possibly increase the virological
response rates in non-responders, particularly in those
infected by HCV-1.
Copyright © 2000 S. Karger AG, Basel
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Introduction
Hepatitis C virus (HCV) infection is a common cause
of chronic liver disease and may progress to liver cirrhosis
and hepatocellular carcinoma in a substantial proportion
of infected individuals [1–4]. At the end of interferon-·
(IFN-·) monotherapy with 3 MIU three times weekly
subcutaneously for 6–12 months, a virological response
with apparent clearance of serum HCV RNA can be
achieved in 30–40% of patients. However, during follow-
up relapses occur in 50–80% of these patients. Therefore,
IFN-· monotherapy with 3 MIU three times weekly sub-
cutaneously for 6–12 months may induce a sustained
virological response in only 10–20% of patients with
chronic hepatitis C [5–8].
Recently published studies indicated a synergistic ther-
apeutic effect of orally administered ribavirin added to
standard IFN-· treatment in chronic hepatitis C [9–12].
Ribavirin (1-ß-D-ribofuranosyl-1,2,4,-triazole-3-carbox-
amide) is a synthetic guanosine analogue with a broad
spectrum of antiviral activities against several DNA and
RNA viruses, including flaviviruses [13–15]. Further-
more, ribavirin exhibits immunomodulatory effects, e.g.
shifting the balance of pro-inflammatory and anti-inflam-
matory cytokines towards a Th1 response by inhibiting
the Th2 cytokine production [16].
Compared with IFN-· monotherapy, combination
treatment with IFN-· and ribavirin for 6–12 months
improves the long-term virological response rates to ap-
proximately 40–50% in patients with chronic hepatitis C
[17–21]. The combination treatment is highly effective in
the retreatment of patients with chronic hepatitis C relaps-
ing after primary IFN-· monotherapy [22–24]. IFN-·/
ribavirin combination therapy has recently been registered
in the United States for treatment of chronic hepatitis C
and is awaiting further approval in several European coun-
tries. However, the therapeutic value of combined IFN-·
and ribavirin retreatment is controversially discussed in
patients with chronic hepatitis C who did not respond to a
primary IFN-· treatment [22, 23, 25–27].
Therefore, the aims of the present study were to evalu-
ate the therapeutic efficacy and the tolerability of retreat-
ment with combined IFN-·/ribavirin as an induction
therapy for 12 weeks followed by maintenance therapy
with IFN-· alone for 9 months in a cohort of patients with
chronic hepatitis C who failed to respond to primary IFN-
· monotreatment. In addition, potential parameters pre-
dicting a sustained response, such as age, sex, disease
duration, ALT, AST, Á-GT, pretreatment viral load, HCV
genotype, and the absence of cirrhosis, were analyzed.
Patients and Methods
In this prospective, open and uncontrolled multicenter trial, 82
patients with chronic hepatitis C not responding to previous IFN-·
monotherapy with a minimal total IFN-· dose of 108 MIU and a
treatment duration of at least 12 weeks were enrolled during Decem-
ber 1995 and November 1996. Patients were eligible when they met
all of the following inclusion criterias: (1) non-response to a previous
IFN-· treatment with persistence of serum HCV RNA; (2) a treat-
ment-free interval of at least 24 weeks; (3) elevated ALT levels; (4) a
positive anti-HCV test; (5) detectable serum HCV RNA; (6) compen-
sated liver disease; (7) baseline hemoglobin of at least 11.0 g/dl, and
(8) age between 18 and 70 years. Demographic, biochemical and
virological pretreatment characteristics are summarized in detail in
table 1. Hepatitis B virus or human immunodeficiency virus type 1
and 2 coinfection as well as concomitant autoimmune disease and
metabolic disorders were excluded by appropriate biochemical and
serological tests. Further exclusion criteria were severe concurrent
diseases, including malignancy, systemic immunosuppressive treat-
ment within the last 24 weeks prior to study begin and a history of
depression. Liver biopsy was performed in all patients before initia-
tion of the primary IFN-· therapy. In 58 patients an additional biop-
sy was obtained within 12 months before retreatment. In the 24
patients, who refused a liver biopsy at this time, the result of the
biopsy before the primary IFN-· treatment was considered for histo-
logical classification (table 1). No histological result in these 24
patients was older than 47 (mean 24; range 12–47) months. Inflam-
matory activity and extent of fibrosis were histologically assessed
according to the 1994 revised classification of chronic hepatitis [28].
Measurement of Serum HCV RNA
Serum HCV RNA was assessed by a standardized qualitative
reverse transcription-polymerase chain reaction (RT-PCR) assay
(Amplicor HCV®, Hoffmann-La Roche, Germany) [29]. Individual
pretreatment serum HCV RNA concentrations and HCV genotype
(according to the classification of Simmonds et al. [30]) were deter-
mined by quantitative RT-PCR (Amplicor Monitor HCV 1.0®, Hoff-
mann-La Roche, Germany) and a reverse hybridization assay (Inno
LiPA HCV II®, Innogenetics, Belgium), respectively [30–33].
Study Design
All patients were treated with 6 MIU IFN-·-2a thrice weekly sub-
cutaneously and ribavirin (14 mg/kg of body weight daily, i.e. 600–
1,200 mg) in two divided doses orally for 12 weeks (fig. 1). Thereafter,
ribavirin therapy was discontinued in all patients, while IFN-· treat-
ment was reduced to 3 MIU thrice weekly and continued for addition-
al 9 months only in patients with undetectable serum HCV RNA at
treatment week 12. The follow-up period was 24 weeks in all patients.
Clinical examination and laboratory assessments, including blood
count and aminotransferases, were performed between pretreatment
weeks 4–12, at the initiation of treatment, every 2 weeks for the first 12
weeks of treatment and monthly thereafter until the end of treatment.
Follow-up visits were scheduled 4, 12 and 24 weeks after discontinua-
tion of treatment. Serum HCV RNA was quantitatively assessed
before initiation of treatment, and qualitatively at 3 and 12 months
during treatment as well as at the end of the follow-up period.
The study protocol was approved by the local ethics committees
for medical research of the participating study centers according to
the Declaration of Helsinki. Because all patients enrolled in the
present study were previous IFN-· non-responders, a retreatment
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Table 1. Demographic, clinical, biochemical, virological and histo-
logical parameters in 82 non-responders to previous IFN-· mono-
therapy with chronic hepatitis C
Demography








Disease duration, years1 12.3B8.7 (1–36)
Primary treatment
Total IFN-· dose, MIU 360B184 (108–1,248)
Duration, months 6.6B3.0 (3–14)
Biochemistry2
ALT, U/l 80B57 (25–338)
AST, U/l 43B34 (4–250)
Á-GT, U/l 52B41 (4–277)
Albumin, g/dl 4.6B0.5 (3.5–5.7)
Bilirubin, Ìmol/l 13.7B6.8 (5.1–35.9)
Prothrombin time, % 101B14 (65–133)
Virology
HCV RNA positive 82







Not assessed 9 (11.0%)
Histology
Inflammatory activity
Minimal to mild 44




ALT = Alanine aminotransferase; AST = aspartate aminotrans-
ferase; Á-GT = Á-glutamyltranspeptidase. The values are given as the
mean B SD (range), or number of patients.
1 Disease duration was defined as the time between the first diag-
nosis of hepatitis C or previous non-A, non-B hepatitis later on con-
firmed as hepatitis C.
2 Normal reference ranges: 4–23 U/l for ALT, 6–18 for AST, 4–28
for Á-GT, 35–55 g/l for albumin, 3.4–23.9 Ìmol/l for bilirubin, 70–
130% for prothrombin time.
3 Pretreatment serum HCV RNA concentration was quantitatively
assessed in 60 of 82 patients.
arm with IFN-· monotherapy as a control group was refused for ethi-
cal reasons [34–37]. Informed written consent was obtained from all
patients.
Definition of Response and Study Endpoints
Virological response to treatment was defined as undetectable
serum HCV RNA by qualitative RT-PCR (sensitivity 1,000 copies/
ml) at treatment week 12 (‘initial virological response’), at the end of
treatment and at the end of follow-up (‘sustained virological re-
sponse’). At the same time points the biochemical response, defined
as an ALT value within the normal range, was evaluated. The prima-
ry endpoint of this study was undetectable serum HCV RNA at the
end of the follow-up period. Secondary efficacy parameters were the
initial virological response and the virological end-of-treatment re-
sponse. As additional secondary endpoints the biochemical re-
sponses were analyzed at the corresponding time points.
Statistical Analysis
Statistical analysis was based on an intention-to-treat methodolo-
gy. Patients who discontinued treatment or were lost during follow-
up were considered as virological and biochemical non-responders.
Data are presented as mean B standard deviation (range). Potential
pretreatment response predicting parameters were identified by uni-
variate analysis. Continuous and dichotomous variables were ana-
lyzed by Student’s t test and the ¯2 test, respectively.
Results
Biochemical and Virological Response
After 12 weeks combined IFN-· and ribavirin retreat-
ment an initial virological response with undetectable
serum HCV RNA at week 12 was achieved in 29 of 82
(35.4%) patients with chronic hepatitis C not responding
to a primary IFN-· monotherapy (table 2). The initial
virological response was associated with normalization of
ALT levels in 21 of 29 of these patients. An isolated initial
biochemical response without clearance of serum HCV
RNA was achieved in 15 of 82 (18.3%) patients. Accord-
ing to the protocol, however, treatment was discontinued
in patients with normal ALT values at week 12, when
serum HCV RNA was still detectable. After reduction of
the IFN-· dose from 3 ! 6 to 3 ! 3 MIU/week and dis-
continuation of ribavirin treatment, a breakthrough with
recurrence of serum HCV RNA was observed in 17 of 29
(58.6%) patients with an initial virological response. The
breakthrough occurred in most patients within treatment
months 4–6 (range 4–8 months). Due to this high break-
through rate, a virological end-of-treatment response was
observed in only 12 of 82 (14.6%) patients. Aminotrans-
ferase levels had normalized in 7 of 12 patients with a
virological end-of-treatment response. During the follow-
up period, 4 of 12 patients with a virological end-of-treat-
ment response relapsed. Thus, a virological sustained
Biochemical response
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Fig. 1. Study design.
Table 2. Biochemical and virological
response to IFN-·/ribavirin retreatment
in 82 non-responders to previous
monotherapy at treatment week 12, at










15 (18.3%) 9 (11.0%) 11 (13.4%)
Virological response 29 (35.4%) 12 (14.6%) 8 (9.8%)
Biochemical and
virological response 21 (25.6%) 7 (8.5%) 6 (7.3%)
Treatment in patients with detectable serum HCV RNA at week 12 was discontinued
regardless of the aminotransferase levels. Virological response: undetectable serum HCV
RNA by qualitative RT-PCR (sensitivity 1,000 copies/ml). Biochemical response: ALT value
within the normal range (^23 U/l).
response with undetectable serum HCV RNA after 24
weeks of follow-up was achieved only in 8 of 82 (9.8%)
primary IFN-· non-responders with chronic hepatitis C.
Seven of these patients also revealed normal ALT values.
Furthermore, in 4 additional patients normalization of
ALT levels was observed at the end of follow-up despite
persisting hepatitis C viremia.
Predictors of a Sustained Virological Response to
Retreatment
Potential clinical, biochemical, virological and histo-
logical pretreatment response predictors were analyzed in
patients with a sustained virological response and com-
pared with patients without a sustained virological re-
sponse (table 3). Using a univariate model, only infection
Age, years
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Table 3. Univariate analysis of pretreatment parameters possibly predicting a sustained virological response to












Disease duration, years1 8.9B6.1 (3–20) 12.7B8.9 (1–36) 0.2401
ALT, U/l 82B37 (32–141) 80B59 (25–338) 0.9280
AST, U/l 43B17 (21–68) 43B36 (2–250) 0.9930
Á-GT, U/l 35B28 (11–92) 54B44 (4–227) 0.2679
Á-GT/ALT 0.48B0.26 (0.18–0.73) 0.80B0.58 (0.09–3.3) 0.1580
Serum HCV RNA concentration,





Absence of cirrhosis 7 42
Cirrhosis 1 32
ALT = Alanine aminotransferase; AST = aspartate aminotransferase; Á-GT = Á-glutamyltranspeptidase. Values
are given as mean B SD (range), or number of patients.
1 Disease duration was defined as the time between first diagnosis of hepatitis C or previously non-A, non-B hepati-
tis later on confirmed as hepatitis C.
2 Pretreatment serum HCV RNA concentration was assessed in 60 of 82 patients.
3 HCV genotype was unclassifiable or not determined in 11 patients.
with HCV genotype 3 was associated with the develop-
ment of a sustained virological response. Clearance of
serum HCV RNA was achieved in 4 of 7 (57.1%) patients
infected with HCV genotype 3 compared with 3 of 60
(5%) patients with HCV genotype 1 infection (p ! 0.001).
In our patients previously not responding to primary IFN-
· treatment, no relation was found between a sustained
response to combined antiviral retreatment and the pa-
tients’ age, disease duration, ALT, AST, Á-GT, Á-GT/
ALT, individual pretreatment serum HCV RNA concen-
tration or the presence of cirrhosis.
Side Effects
Nearly all patients (n = 77; 93.9%) developed at least
one adverse event during the treatment period. Most side
effects (n = 284) occurred during the initial 12 weeks of
IFN-·/ribavirin combination therapy (table 4). Mild to
moderate flu-like symptoms were the most frequently
observed adverse events. During ribavirin treatment
19.5% of the treated patients developed anemia with a
serum hemoglobin level of !11.0 g/dl. The ribavirin dose
was reduced in 14 patients to 7 mg/kg body weight daily
or discontinued (n = 4 patients) due to hemoglobin levels
of !10.0 g/dl, fatigue, weakness, dizziness, depression,
nausea, and vomiting. A reduction of the IFN-· dose from
6 to 3 MIU thrice weekly before week 12 was necessary in
7 patients due to leukopenia, weakness, depression, myal-
gia, arthralgia, and headache, respectively. In 3 additional
patients, both drugs were discontinued due to adverse
events at treatment weeks 1 (nausea, diarrhea), 4 (depres-
sion), and 12 (anemia, nausea, dizziness), respectively.
During IFN-· treatment with 3 ! 3 MIU/week (weeks
13–52) most side effects improved or resolved. Further
dose reductions were not required. After discontinuation
of treatment, all reported side effects were fully reversible.
Serious adverse events were not observed in any patient
during the entire treatment period. The drop-out of 1
patient at month 4 of treatment was not related to side
effects. After the end of treatment, 3 patients did not
attend the scheduled follow-up visit at week 24.
Flu-like
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Table 4. Side effects of combined IFN-·/ribavirin retreatment
(weeks 1–12) followed by IFN-· monotherapy (weeks 13–52) in 82







Chills and fever 56 (68.3%) 2 (6.9%)
Fatigue 46 (56.1%) 6 (20.7%)
Headache 22 (26.8%) 4 (13.8%)
Myalgia 13 (15.9%) 2 (6.9%)
Arthralgia 8 (9.8%) 2 (6.9%)
Gastrointestinal
Nausea 21 (25.6%) 1 (3.5%)
Loss of appetite 9 (11.0%) 0
Diarrhea 4 (4.9%) 0
CNS
Insomnia 11 (13.4%) 2 (6.9%)
Depression 8 (9.8%) 1 (3.5%)
Disturbances of concentration 2 (2.4%) 2 (6.9%)
Weakness 7 (8.5%) 0
Dizziness 9 (11.0%) 0
Dermatological
Hair loss 7 (8.5%) 4 (13.8%)
Pruritus 6 (7.3%) 0
Rash 2 (2.4%) 0
Sicca syndrome 3 (3.7%) 1 (3.5%)
Respiratory
Dry cough 6 (7.3%) 0
Dyspnea 1 (1.2%) 0
Blood count
Anemia1 16 (19.5%) 1 (3.5%)
Leucopenia2 20 (24.4%) 2 (6.9%)
Thrombocytopenia3 7 (8.5%) 3 (10.4%)




In this multicenter trial, efficacy and tolerability of
combined IFN-· and ribavirin treatment were prospec-
tively assessed in patients with chronic hepatitis C not
responding to a previous IFN-· treatment. This trial was
designed in 1994 and it was originally anticipated that
ribavirin may exhibit direct antiviral effects. Thus, the
rational for the study design was an induction phase with
IFN-· plus ribavirin to achieve optimal initial response
rates followed by IFN-· monotherapy to maintain the
virological response. With respect to the reported poor
response rates in non-responders receiving IFN-· retreat-
ment [34–37], a control group with patients receiving
IFN-· alone was not justifiable for ethical considerations.
As previously described, sustained loss of serum HCV
RNA regularly leads to considerable histological improve-
ment [38, 39]. Thus, a second liver biopsy after retreat-
ment was not performed in our patients and serum HCV
RNA 24 weeks after treatment was analyzed as the prima-
ry efficacy parameter in this study.
In the present study, including 82 primary IFN-·
non-responders, a virological sustained response was
achieved in only 9.8% of patients retreated with a combi-
nation of IFN-· and ribavirin. Despite an initially high
virological response rate of 35.4% after 12 weeks of com-
bination therapy, a virological end-of-treatment response
was observed in only 14.6% of the retreated non-respond-
ers with chronic hepatitis C. Breakthrough with the recur-
rence of serum HCV RNA was observed in 15 of 17
patients with an initial response within 3 months after
discontinuation of ribavirin therapy and IFN-· dose re-
duction. In the remaining 2 patients’ breakthrough oc-
curred at 7 and 8 months, respectively. Thus, low-dose
IFN-· monotherapy is not able to maintain the high ini-
tial response rate induced by IFN-·/ribavirin induction
therapy. However, as in untreated patients receiving com-
bination therapy, the relapse rate in patients with a viro-
logical end-of-treatment response was lower than de-
scribed for patients after IFN-· monotherapy [20, 21].
In previously published pilot studies concerning
IFN-·/ribavirin retreatment in IFN-· non-responders,
the reported sustained response rates varied considerably
between 0 and 30% [22, 23, 25–27]. In contrast to the
treatment schedule used in this trial, the duration of IFN-
·/ribavirin retreatment was in general at least 24 weeks.
In the present study, the sustained low virological re-
sponse rate to IFN-·/ribavirin retreatment appears to be
related to the short duration of ribavirin treatment and
possibly to early IFN-· dose reduction. However, the
majority of the previous studies revealed, in accordance
with our results, low overall virological sustained response
rates of approximately 10% in non-responders with
chronic hepatitis C [22, 25, 27]. With respect to the HCV
genotype distribution, the present study showed a benefi-
cial therapeutic effect of IFN-·/ribavirin retreatment in
non-responders infected by HCV genotypes 3 with a viro-
logical sustained response rate of 57.1%. The results of
this trial indicate that the retreatment schedule with an
IFN-·/ribavirin induction therapy followed by a low-dose
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IFN-· monotherapy seems not to be effective in non-
responders, infected with HCV genotype 1. Thus, the
varying response rates, reported in the published pilot
studies, may be explained by small study populations and
the HCV genotype distribution.
In the present study, other host and viral factors associ-
ated with a response to antiviral therapy in untreated
patients with chronic hepatitis C, including sex, presence
of cirrhosis and pretreatment viral load [40, 41], showed
no predictive role in the setting of IFN-·/ribavirin retreat-
ment in non-responders. The lack of an association be-
tween the individual serum HCV RNA concentrations
and the response to treatment in our patients may be
explained by the limitations of the HCV RNA quantifica-
tion assay used in this study. As previously described,
amplification of this commercially available RT-PCR
assay is not linear and not genotype-independent leading
to an underestimation of the serum HCV RNA concentra-
tion in patients with high viremia (1106 copies/ml) and
patients infected with genotype HCV-2 and 3 [30, 31]. 
During IFN-·/ribavirin retreatment, side effects oc-
curred in most of our patients (93.9%) within the first 3
months of treatment. Most side effects were mild and
transient. However, dose reduction or discontinuation of
IFN-· and/or ribavirin therapy were required in 28 of 82
(34.1%) patients due to the reported adverse events. After
discontinuation of treatment, all side effects were fully
reversible.
In summary, retreatment with IFN-· and ribavirin in
the applied dose regimen seems to have a beneficial thera-
peutic effect only in non-responders with chronic hepati-
tis C infected with HCV genotype 3, while it is of low effi-
cacy in non-responders with HCV genotype 1 infection.
Thus, similar to untreated patients with chronic hepatitis
C, genotype-dependent therapeutic strategies should be
evaluated in the retreatment of non-responders. Further-
more, the potential therapeutic value of a high-dose
IFN-· induction and maintenance therapy as well as pro-
longed treatment with ribavirin, and the addition of
amantadin has to be elucidated in future studies.
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